DSAM Partners’s Teva Pharmaceuticals TEVA Stock Holding History

DSAM Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-76,000	Closed	-$4.99M	–	38
2015 Q4	$4.99M	Buy	+76,000	New	+$4.7M	1.28%	20

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

DSAM Partners's TEVA Position: Q1 2016 in Review

DSAM Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 76,000 shares — an estimated $4.99M sold.

DSAM Partners first reported a position in TEVA in Q4 2015 and held it in 1 quarter. The position peaked at $4.99M in Q4 2015. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

DSAM Partners reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
DSAM Partners sold 76,000 Teva Pharmaceuticals shares in Q1 2016, an estimated $4.99M.
DSAM Partners first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 1 quarter.
DSAM Partners's Teva Pharmaceuticals position peaked at $4.99M in Q4 2015.
836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on DSAM Partners's 13F filing for Q1 2016, filed 13 May 2016.